Prognosis-related genes participate in immunotherapy of renal clear cell carcinoma possibly by targeting dendritic cells

Abstract

Tumor immunotherapy has become one of the most promising approaches to tumor treatment. This study aimed to screen genes involved in the response of clear cell renal cell carcinoma (ccRCC) to immunotherapy and analyze their function. Based on the Gene Expression Omnibus and The Cancer Genome Atlas datasets, we screened out nine differentially expressed genes (TYROBP, APOC1, CSTA, LY96, LAPTM5, CD300A, ALOX5, C1QA, and C1QB) associated with clinical traits and prognosis. A risk signature constructed by these nine genes could predict the survival probability for patients at 1 year, 3 years, and 5 years. The immune checkpoint blockade response rate in the high-risk group was significantly higher than in the low-risk group (49.25% vs. 24.72%, p ≤ 0.001). The nine prognosis-related genes were negatively correlated with activated dendritic cells in the low-risk group but not in the high-risk group. qRT-PCR, immunohistochemistry, and immunofluorescence showed that the nine prognosis-related genes were associated with dendritic cell activity and the PD-1 positive staining rate. In conclusion, the nine prognosis-related genes have a high prognostic value. The patients in the high-risk group were more likely to benefit from immunotherapy, and the mechanism might be related to the release of dendritic cell-mediated immunosuppression.

Comprehensive analyses for the coagulation and macrophage-related genes to reveal their joint roles in the prognosis and immunotherapy of lung adenocarcinoma patients

“…In the correlation analysis, we found that the 10 COMAR genes were positively correlated with immune checkpoint expression, such as PD-L1 and the IPS with anti-PD1 plus anti-CTLA4 or anti-PD1 along immunotherapy in both patient specimens and LUAD cell lines (Figure 8; Supplementary Figure S6A). Most of the genes in the COMAR model have also been reported to be positively correlated with PD-L1 expression and respond to ICB immunotherapy in multiple cancers (47,(88)(89)(90)(91)(92)(93), which was consistent with the results of our study. These suggested that the 10 COMAR genes might serve as potential targets for ICB immunotherapy.…”

Identification of prognostic models for glycosylation-related subtypes and tumor microenvironment infiltration characteristics in clear cell renal cell cancer

“…Patients treated for renal cell carcinoma with sunitinib in the first line may benefit from using KDR as a predictive biomarker of clinical outcome [ 28 ]. According to reports, LY96 may target dendritic cells in immunotherapy for renal cell carcinoma [ 29 ]. In clear cell renal cell carcinoma, TEK is a new prognostic marker [ 30 ].…”

APOC1 reduced anti-PD-1 immunotherapy of nonsmall cell lung cancer via the transformation of M2 into M1 macrophages by ferroptosis by NRF2/HO-1

“…APOC1 gene promoted cell growth of NSCLC. Fang et al [35] reported that APOC1 participates in immunotherapy of renal clear cell carcinoma. These data suggest that the APOC1 gene promoted cell growth of NSCLC through anti-PD-1 immunotherapy.…”